Treatments for cancers, infections, autoimmune diseases and other life-threatening disorders
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
27
NCT04967690
A Dose Escalation Study to Estimate MTD, DLTs and Pharmacokinetics After a Single Intracranial Dose of SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed GBM
Phase: Phase 1
Role: Lead Sponsor
Start: Jan 31, 2024
Completion: Dec 31, 2025
Loading map...